Study suggests flubendazole may help curb Guinea worm in dogs
Bottom line
A new two-year cluster-randomized study in PLoS Neglected Tropical Diseases found that flubendazole was associated with fewer emerging Dracunculus medinensis worms in dogs in Chad, a notable development for Guinea worm eradication efforts. The study enrolled villages rather than individual dogs, with 29 villages assigned to receive flubendazole and 27 serving as controls, building on an earlier dog trial that had not shown a clear benefit at the individual-animal level. The broader context is important: human Guinea worm cases have fallen by more than 99.9% since the 1980s, but persistent infections in dogs, especially in Chad, have become one of the main barriers to finishing eradication. (pubmed.ncbi.nlm.nih.gov)
Why it matters: For veterinary professionals, this study adds evidence that a drug-based intervention may help reduce transmission pressure in an animal reservoir that public health programs have struggled to control with behavior change alone. Guinea worm has no approved medicine or vaccine for prevention or treatment, and current control efforts rely heavily on surveillance, tethering infected dogs, safe disposal of fish entrails, water treatment, and community compliance. If flubendazole can reliably reduce worm emergence at the village level, it could become a useful adjunct to those field measures, especially in hard-to-manage endemic settings. (cdc.gov)
What to watch: Watch for follow-up data on effect size, implementation feasibility, safety, and whether eradication programs move toward broader operational use of flubendazole alongside tethering and surveillance. (pubmed.ncbi.nlm.nih.gov)
Key facts
- Study type
- Two-year cluster-randomized study
- Journal
- PLoS Neglected Tropical Diseases
- Drug
- Flubendazole
- Species
- Dogs
- Location
- Chad
- Clusters assigned to treatment
- 29 villages
- Clusters assigned to control
- 27 villages
- Finding
- Flubendazole was associated with fewer emerging Dracunculus medinensis worms
- Context
- Guinea worm has no approved medicine or vaccine for prevention or treatment
A newly published PLoS Neglected Tropical Diseases study reports that flubendazole reduced emerging Dracunculus medinensis worms in dogs in Chad over a two-year period, offering fresh evidence that veterinary intervention could help address one of the last major obstacles in Guinea worm eradication. The trial used a cluster-randomized design, assigning 29 villages to flubendazole treatment and 27 to no treatment, reflecting a shift away from dog-level analysis toward village-level impact. (pubmed.ncbi.nlm.nih.gov)
That design change matters because earlier work with flubendazole in dogs did not show a significant effect under the tested regimen, and investigators later argued that the original trial may have been asking the wrong question. In a 2026 methods paper, the same research group said the measurable benefit of flubendazole was more likely to appear at the population level and over a longer time horizon, especially in remote settings where follow-up of individual dogs is difficult and attrition is high. (pmc.ncbi.nlm.nih.gov)
The backdrop is a near-eradication story complicated by an animal reservoir. Guinea worm disease has dropped from an estimated 3.5 million human cases annually in the mid-1980s to 15 cases in 2024 and 10 provisional human cases in 2025, according to eradication partners. But infections in dogs, particularly in Chad, have repeatedly threatened progress. CDC reported 886 animal infections globally in 2023, and noted that animal infections, primarily in dogs in Cameroon and Chad, remain a key threat to near-term eradication. The Carter Center says Guinea worm was first detected in animals in Chad in 2012, often linked to dogs eating fish or fish waste containing infective larvae. (journals.plos.org)
The new study also fits with a growing body of work suggesting that no single intervention will be enough. A separate PLoS Neglected Tropical Diseases analysis published earlier this year found that therapeutic and behavioral interventions together were associated with fewer emerging worms in dogs in Chad, with modeled effects becoming clearer after proactive tethering and sustained flubendazole exposure had been in place over time. That aligns with the eradication program’s current strategy, which combines infected-dog tethering, safe disposal of fish entrails, larvicide treatment of unsafe water, reporting incentives, and intensive surveillance. (journals.plos.org)
Direct outside commentary on the new paper appears limited so far, but the broader expert view is consistent: animal infections have changed the endgame for Guinea worm eradication. CDC has said there is no medicine available to prevent or treat dracunculiasis, underscoring why evidence for a veterinary pharmaceutical tool is noteworthy. At the same time, the field has been cautious before. Earlier flubendazole work in ferrets and dogs suggested biologic promise, including reduced larval infectivity in laboratory settings, but did not translate into a clear field effect in the first dog trial. (cdc.gov)
Why it matters: For veterinary professionals, especially those following One Health, parasitology, and global disease control, this is less about a new companion-animal therapy and more about the role of veterinary medicine in finishing a human disease eradication campaign. Dogs in Chad are not just incidental hosts; they are central to transmission dynamics. A practical intervention that reduces worm emergence could lower environmental contamination risk and complement nonpharmaceutical controls that depend heavily on community adherence. It also shows how veterinary field trials may need different endpoints than conventional clinical studies, focusing on population-level transmission outcomes rather than only individual-animal cure. (journals.plos.org)
There are still important unanswered questions. The abstract-level reporting available so far does not fully spell out the magnitude of benefit, operational costs, adverse-event profile, or how easily this approach could scale across endemic regions. And because Guinea worm eradication programs already rely on layered interventions, separating the drug’s contribution from concurrent behavior-change measures will remain a practical challenge, even with stronger study design. That said, the signal is meaningful enough to put flubendazole back into the conversation after earlier disappointment. (pubmed.ncbi.nlm.nih.gov)
What to watch: The next steps are likely to be close scrutiny of the full study data, discussion among eradication partners about operational deployment, and additional evidence on how flubendazole performs when layered into real-world surveillance and tethering programs in Chad and other remaining endemic settings. (cdc.gov)